Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders
Anteris Technologies Global Corp. (NASDAQ: AVR) announced the adjournment of its Special Meeting of Stockholders due to lack of required quorum. The meeting has been rescheduled for September 29, 2025, at 8:00 a.m. Central time.
The virtual meeting will be held via webcast, maintaining the original record date of August 11, 2025. Stockholders who haven't voted can still do so, with proxy submissions due by September 28, 2025, at 11:59 p.m. Eastern time for online/telephone votes, and September 26, 2025 for mail-in proxies. CDI holders must submit voting instructions by September 25, 2025, at 5:00 p.m. Central time.
Anteris Technologies Global Corp. (NASDAQ: AVR) ha annunciato l'annullamento della Special Meeting of Stockholders per mancanza di quorum richiesto. La riunione è stata riprogrammata per il 29 settembre 2025, alle 8:00 (ora centrale).
La riunione virtuale si svolgerà tramite webcast, mantenendo la data di registrazione del 11 agosto 2025. Gli azionisti che non hanno votato possono ancora farlo, con le presentazioni di procura entro il 28 settembre 2025, alle 23:59 (ora orientale) per voti online/telefonici, e il 26 settembre 2025 per le procure inviate per posta. I detentori CDI devono inviare le istruzioni di voto entro il 25 settembre 2025, alle 17:00 (ora centrale).
Anteris Technologies Global Corp. (NASDAQ: AVR) anunció la postergación de su Reunión Especial de Accionistas debido a la falta de quórum requerido. La reunión se ha reprogramado para el 29 de septiembre de 2025, a las 8:00 a.m. hora central.
La reunión virtual se llevará a cabo por webcast, manteniendo la fecha de registro del 11 de agosto de 2025. Los accionistas que no hayan votado aún pueden hacerlo, con las presentaciones de poderes hasta el 28 de septiembre de 2025, a las 11:59 p.m. hora del este para votos en línea/telefónicos, y el 26 de septiembre de 2025 para poderes por correo. Los poseedores de CDI deben enviar instrucciones de voto antes de el 25 de septiembre de 2025, a las 5:00 p.m. hora central.
Anteris Technologies Global Corp. (NASDAQ: AVR)는 필요한 의석 미달로 특별주주총회가 연기되었음을 발표했습니다. 회의는 2025년 9월 29일 오전 8:00(중부 표준시)로 재일정되었습니다.
가상 회의는 webcast를 통해 진행되며 2025년 8월 11일의 기록일을 유지합니다. 아직 표결하지 않은 주주들은 온라인/전화 투표를 위한 위임장 제출 마감이 2025년 9월 28일 오후 11:59(동부 시간), 우편 위임장은 2025년 9월 26일까지 제출할 수 있습니다. CDI 보유자는 중부 표준시로 2025년 9월 25일 오후 5:00까지 투표 지침을 제출해야 합니다.
Anteris Technologies Global Corp. (NASDAQ: AVR) a annoncé le report de sa Réunion Spéciale des Actionnaires en raison d'un quorum insuffisant. La réunion a été reprogrammée pour le 29 septembre 2025, à 8h00, heure centrale.
La réunion virtuelle se tiendra par webcast, en conservant la date d'enregistrement du 11 août 2025. Les actionnaires qui n'ont pas encore voté peuvent le faire, avec les soumissions de procurations dûes au 28 septembre 2025, à 23h59, heure de l'Est pour les votes en ligne/téléphoniques, et le 26 septembre 2025 pour les procurations par courrier. Les détenteurs CDI doivent envoyer leurs instructions de vote d'ici le 25 septembre 2025, à 17h00, heure centrale.
Anteris Technologies Global Corp. (NASDAQ: AVR) gab die Vertagung seiner Sondersitzung der Aktionäre aufgrund mangelnder quorum bekannt. Die Versammlung wurde auf den 29. September 2025, 08:00 Uhr Zentralzeit neu terminiert.
Die virtuelle Versammlung wird per Webcast abgehalten, wobei das ursprüngliche Aufzeichnungsdatum vom 11. August 2025 beibehalten wird. Aktionäre, die noch nicht abgestimmt haben, können dies weiterhin tun, mit Stimmrechtsvertretungen, die bis 28. September 2025, 23:59 Uhr Eastern Time für Online-/Telefonstimmen eingereicht werden, und 26. September 2025 für Stimmrechtsvertretungen per Post. CDI-Inhaber müssen ihre Abstimmungsanweisungen bis 25. September 2025, 17:00 Uhr Central Time einreichen.
Anteris Technologies Global Corp. (NASDAQ: AVR) أعلنت عن تأجيل اجتماع المساهمين الخاص بسبب نقص النصاب المطلوب. وتم إعادة جدولة الاجتماع ليعقد في 29 سبتمبر 2025، الساعة 8:00 صباحاً بتوقيت الوسط.
سيُعقد الاجتماع الافتراضي عبر البث المباشر، مع الاحتفاظ بتاريخ السجل الأصلي وهو 11 أغسطس 2025. يمكن للمساهمين الذين لم يصوتوا بعد القيام بذلك، مع تقديم التوكيلات حتى 28 سبتمبر 2025، الساعة 11:59 مساءً بتوقيت شرق الولايات المتحدة للصوت عبر الإنترنت/الهاتف، و26 سبتمبر 2025 للوكلاء بالبريد. يجب على حاملي CDI إرسال تعليمات voting حتى 25 سبتمبر 2025، الساعة 5:00 مساءً بتوقيت الوسط.
Anteris Technologies Global Corp. (NASDAQ: AVR) 宣布由于缺乏所需法定人数，特别股东大会延期。会议已重新安排为2025年9月29日，中央时间上午8:00。
虚拟会议将通过网络直播举行，保持原定的2025年8月11日的记录日。尚未投票的股东仍可投票，在线/电话投票的代理提交截止为2025年9月28日，美国东部时间晚上11:59，邮寄代理的截止日期为2025年9月26日。CDI持有者必须在2025年9月25日，中央时间下午5:00前提交投票指示。
- None.
- None.
MINNEAPOLIS and BRISBANE, Australia, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that after convening its Special Meeting of Stockholders (the “Special Meeting”) virtually on Thursday, September 18, 2025, at 5:00 p.m. Central time (being 8:00 a.m. AEST on Friday, September 19, 2025), the Company adjourned the Special Meeting until Monday, September 29, 2025 at 8:00 a.m. Central time (being 11:00 p.m. AEST on Monday, September 29, 2025). The Company will also be holding its adjourned Special Meeting virtually, via live webcast at www.virtualshareholdermeeting.com/AVR2025SM. The record date for the Special Meeting, August 11, 2025 (the “Record Date”), is unchanged and applies to the adjourned Special Meeting.
The Special Meeting has been adjourned, without any business being conducted, due to lack of the required quorum. The Special Meeting was adjourned to allow additional time for the Company’s stockholders to vote on the proposals set forth in the Company’s definitive Proxy Statement for the Special Meeting (the “Proxy Statement”), which was filed with the Securities and Exchange Commission (the “SEC”) on August 18, 2025. The Company’s Board of Directors unanimously recommends that you vote FOR the proposals identified in the Company’s Proxy Statement.
Voting Details
If you have already voted your shares of Common Stock or directed CHESS Depositary Nominees Pty Ltd (“CDN”) to vote your CHESS Depositary Interests (“CDIs”) by completing the CDI Voting Instruction Form and you do not desire to change your vote, your prior vote will remain voted without the need for you to take any additional action.
If you held shares of Common Stock on the Record Date and have not yet voted, you may do so now using the directions provided in the Proxy Statement. To ensure that proxies are received in time to be counted prior to the Special Meeting, proxies submitted via the Internet or by telephone should be received by 11:59 p.m. Eastern time on September 28, 2025 (being 1:59 p.m. AEST on September 29, 2025), and proxies submitted by mail should be received by the close of business on September 26, 2025 (being 7:00 a.m. AEST on September 27, 2025).
If you held CDIs on the Record Date and you have not yet directed CDN to vote by completing the CDI Voting Instruction Form, you may submit your completed CDI Voting Instruction Form to Computershare, the agent the Company has designated for the collection and processing of voting instructions from the Company’s CDI holders, prior to 5:00 p.m. Central time on September 25, 2025 (being 8:00 a.m. AEST on September 26, 2025) in accordance with the instructions on the CDI Voting Instruction Form.
Important Additional Information
The Company filed the definitive Proxy Statement with the SEC on August 18, 2025, which should be read in conjunction with this notice. To the extent information in this notice updates or conflicts with information contained in the Proxy Statement, the information in this notice is more current. STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) FILED BY THE COMPANY AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT ANY SOLICITATION. Stockholders may obtain a free copy of the Proxy Statement and the other relevant materials, and any other documents filed by the Company with the SEC, at the SEC’s website at https://www.sec.gov or on the “SEC Filings” section of the Company’s website at https://www.anteristech.com/investors.
About Anteris
Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.
Anteris’ lead product, the DurAVR® Transcatheter Heart Valve (“THV”), was designed in partnership with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “intend,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements include, but are not limited to, any statements regarding the uncertainties related to the presence of a quorum at the Special Meeting and receipt of stockholder approval of the proposals presented at the Special Meeting. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under “Risk Factors” in Anteris’ Annual Report on Form 10-K filed with the SEC on March 12, 2025, as amended on April 29, 2025, and Quarterly Reports on Form 10-Q filed with the SEC on May 13, 2025 and August 11, 2025. Readers are cautioned not to place undue reliance on forward-looking statements, and except as required by law, the Company does not assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.
| For more information: | |
| Investor Relations investor@anteristech.com Debbie Ormsby Anteris Technologies Global Corp. +61 1300 550 310 | +61 7 3152 3200 | Investor Relations (US) mchatterjee@bplifesciences.com Malini Chatterjee, Ph.D. Blueprint Life Science Group +1 917 330 4269 |
FAQ
When is the rescheduled Anteris Technologies (AVR) Special Meeting of Stockholders?
What is the voting deadline for Anteris Technologies (AVR) stockholders?
How can shareholders access the Anteris Technologies virtual Special Meeting?
What is the record date for the Anteris Technologies Special Meeting?
When is the voting deadline for Anteris Technologies CDI holders?
